http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011129533-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0973b70303a6689b2d3eca1118129321 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1694 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1688 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
filingDate | 2011-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75f6fb2802d52791ced45e33b1ef190b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb9c64305b634d6ee0aa814f5ae5ff32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d44339d9ac21706c9c095553a69adc47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7ad3296f8ad968927f5e3aad7081eb2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa3cd5546f02278734368778580ec3ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3432f65203340f3ebd126e70fcc8c72b |
publicationDate | 2011-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2011129533-A1 |
titleOfInvention | Porous drug matrices and methods of manufacture thereof |
abstract | Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11318107-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019165208-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11504342-B2 |
priorityDate | 1999-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 3096.